AUS
NZ
UK
CA
USA
IND
Genedrive plc (LSE:GDR), a leader in point-of-care pharmacogenetic testing, has announced the receipt of an initial order for its CYP2C19-ID Kit and associated instruments, valued at approximately £0.1 million. This order follows the recent endorsement by the UK's National Institute for Health and Care Excellence (NICE), which recommended the use of the Genedrive® CYP2C19-ID test for guiding clopidogrel therapy in patients who have experienced an ischaemic stroke (IS) or transient ischaemic attack (TIA).
NICE Endorsement and Its Implications
NICE’s final guidance has positioned the Genedrive® CYP2C19-ID test as the preferred choice for point-of-care genotyping strategies. This recommendation is a significant milestone for Genedrive, as it endorses the company's test for immediate use in the UK healthcare system. The CYP2C19 genotyping is crucial for determining the suitability of clopidogrel, a common antiplatelet medication, in preventing further strokes in patients who have already suffered from IS or TIA.
Implementation at Greater Manchester's Comprehensive Stroke Centre
The initial order for the CYP2C19-ID Kit will support an implementation assessment at Greater Manchester's Comprehensive Stroke Centre (CSC), located within the Manchester Centre for Clinical Neurosciences at Salford Royal Hospital. The CSC is part of the Northern Care Alliance NHS Foundation Trust and is the largest hyperacute stroke unit (HASU) in England, with over 2,000 stroke patient admissions annually. The assessment aims to evaluate the clinical and operational benefits of using the Genedrive® CYP2C19-ID test in a real-world healthcare setting, with a particular focus on its impact on patient outcomes across Greater Manchester.
HASUs, as part of the UK's Integrated Stroke Delivery Network, play a critical role in providing care during the first 72 hours following a stroke. The rapid assessment and treatment of stroke patients are essential to improving recovery chances and reducing the risk of subsequent strokes. The implementation of the Genedrive® test at the CSC is expected to demonstrate its effectiveness in supporting these goals.
Financial and Strategic Impact
The NICE guidance not only supports the use of the Genedrive® CYP2C19-ID test in point-of-care settings but also highlights its versatility for use in traditional laboratory environments. This flexibility allows the Genedrive® System to serve as a cost-effective alternative to more expensive laboratory platforms, particularly in scenarios where high-throughput batch processing is unnecessary.
The potential financial impact on the NHS is substantial. By implementing CYP2C19 genotyping for IS/TIA patients, the NHS could realize savings of approximately £91 million in the first year and up to £454 million over five years. These savings stem from improved patient outcomes, reduced adverse drug reactions, and more efficient use of healthcare resources.
